S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
Buy THIS stock before Taiwan is attacked (Ad)
FuelCell Is Back To Realistic Valuation
Nigeria's central bank chief arrested after being suspended by president
Buy THIS stock before Taiwan is attacked (Ad)
North Dakota tribe buys idle oil pipeline from Enbridge
Ukrainian President Volodymyr Zelenskyy says ‘counteroffensive, defensive actions’ taking place in war with Russia
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
Boris Johnson's bombshell exit from Parliament leaves UK politics reeling
Can a chatbot preach a good sermon? Hundreds attend church service generated by ChatGPT to find out
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
Buy THIS stock before Taiwan is attacked (Ad)
FuelCell Is Back To Realistic Valuation
Nigeria's central bank chief arrested after being suspended by president
Buy THIS stock before Taiwan is attacked (Ad)
North Dakota tribe buys idle oil pipeline from Enbridge
Ukrainian President Volodymyr Zelenskyy says ‘counteroffensive, defensive actions’ taking place in war with Russia
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
Boris Johnson's bombshell exit from Parliament leaves UK politics reeling
Can a chatbot preach a good sermon? Hundreds attend church service generated by ChatGPT to find out
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
Buy THIS stock before Taiwan is attacked (Ad)
FuelCell Is Back To Realistic Valuation
Nigeria's central bank chief arrested after being suspended by president
Buy THIS stock before Taiwan is attacked (Ad)
North Dakota tribe buys idle oil pipeline from Enbridge
Ukrainian President Volodymyr Zelenskyy says ‘counteroffensive, defensive actions’ taking place in war with Russia
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
Boris Johnson's bombshell exit from Parliament leaves UK politics reeling
Can a chatbot preach a good sermon? Hundreds attend church service generated by ChatGPT to find out
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
Buy THIS stock before Taiwan is attacked (Ad)
FuelCell Is Back To Realistic Valuation
Nigeria's central bank chief arrested after being suspended by president
Buy THIS stock before Taiwan is attacked (Ad)
North Dakota tribe buys idle oil pipeline from Enbridge
Ukrainian President Volodymyr Zelenskyy says ‘counteroffensive, defensive actions’ taking place in war with Russia
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
Boris Johnson's bombshell exit from Parliament leaves UK politics reeling
Can a chatbot preach a good sermon? Hundreds attend church service generated by ChatGPT to find out
NYSE:HAE

Haemonetics (HAE) Stock Forecast, Price & News

$88.14
-0.19 (-0.22%)
(As of 06/9/2023 ET)
Compare
Today's Range
$87.56
$88.87
50-Day Range
$80.84
$89.45
52-Week Range
$58.23
$91.39
Volume
180,972 shs
Average Volume
275,116 shs
Market Capitalization
$4.45 billion
P/E Ratio
39.52
Dividend Yield
N/A
Price Target
$103.17

Haemonetics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
17.0% Upside
$103.17 Price Target
Short Interest
Healthy
2.16% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.54
Upright™ Environmental Score
News Sentiment
-0.09mentions of Haemonetics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$191,992 Sold Last Quarter
Proj. Earnings Growth
11.55%
From $3.55 to $3.96 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.18 out of 5 stars

Medical Sector

261st out of 987 stocks

Surgical & Medical Instruments Industry

27th out of 95 stocks


HAE stock logo

About Haemonetics (NYSE:HAE) Stock

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot including collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Receive HAE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Haemonetics and its competitors with MarketBeat's FREE daily newsletter.

HAE Stock News Headlines

Haemonetics (NYSE:HAE) Downgraded by StockNews.com to "Buy"
[Strong Buy Alert] Is this laser stock in your portfolio?
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? There are very few opportunities like this in today's bear market... But our analysts identified a tiny defense company landing billions of dollars in contracts every year.
[Strong Buy Alert] Is this laser stock in your portfolio?
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? There are very few opportunities like this in today's bear market... But our analysts identified a tiny defense company landing billions of dollars in contracts every year.
StockNews.com Upgrades Haemonetics (NYSE:HAE) to Strong-Buy
Haemonetics Corporation: Premium Blood Play
Haemonetics (NYSE:HAE) Releases FY 2024 Earnings Guidance
Barrington Reaffirms Their Buy Rating on Haemonetics (HAE)
See More Headlines

HAE Price History

HAE Company Calendar

Last Earnings
2/07/2023
Today
6/10/2023
Next Earnings (Estimated)
8/09/2023
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Supplies
Sector
Medical
CUSIP
40502410
Employees
3,034
Year Founded
1971

Price Target and Rating

Average Stock Price Forecast
$103.17
High Stock Price Forecast
$115.00
Low Stock Price Forecast
$88.00
Forecasted Upside/Downside
+17.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Net Income
$115.40 million
Pretax Margin
12.10%

Debt

Sales & Book Value

Annual Sales
$1.17 billion
Cash Flow
$4.97 per share
Book Value
$16.22 per share

Miscellaneous

Free Float
49,707,000
Market Cap
$4.45 billion
Optionable
Optionable
Beta
0.43

Social Links


Key Executives

  • Mr. Christopher A. SimonMr. Christopher A. Simon (Age 59)
    CEO, Pres & Director
    Comp: $1.88M
  • Mr. Josep Lluis Llorens (Age 60)
    Exec. VP of Global Manufacturing & Supply Chain
    Comp: $718.76k
  • Mr. Stewart W. StrongMr. Stewart W. Strong (Age 56)
    Pres of Global Hospital
    Comp: $918.03k
  • Mr. James C. D'Arecca CPA (Age 52)
    CFO, Exec. VP & Financial Officer
  • Ms. Farris Maryanne Maunsell (Age 48)
    VP, Chief Accounting Officer & Principal Accounting Officer
  • Ms. Anila  LingamneniMs. Anila Lingamneni (Age 55)
    Exec. VP & CTO
  • Ms. Olga Guyette
    Sr. Director of Investor Relations
  • Carla Burigatto
    VP of Communications
  • Mr. Rajeev Varma
    Sr. VP of Strategy & Corp. Devel.
  • Ms. Laurie A. MillerMs. Laurie A. Miller
    Sr. VP & Chief HR Officer













HAE Stock - Frequently Asked Questions

Should I buy or sell Haemonetics stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Haemonetics in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HAE shares.
View HAE analyst ratings
or view top-rated stocks.

What is Haemonetics' stock price forecast for 2023?

6 brokers have issued twelve-month price targets for Haemonetics' stock. Their HAE share price forecasts range from $88.00 to $115.00. On average, they predict the company's stock price to reach $103.17 in the next twelve months. This suggests a possible upside of 17.0% from the stock's current price.
View analysts price targets for HAE
or view top-rated stocks among Wall Street analysts.

How have HAE shares performed in 2023?

Haemonetics' stock was trading at $78.65 at the beginning of the year. Since then, HAE shares have increased by 12.1% and is now trading at $88.14.
View the best growth stocks for 2023 here
.

Are investors shorting Haemonetics?

Haemonetics saw a drop in short interest in April. As of April 30th, there was short interest totaling 1,040,000 shares, a drop of 21.2% from the April 15th total of 1,320,000 shares. Based on an average daily volume of 328,200 shares, the days-to-cover ratio is currently 3.2 days. Approximately 2.1% of the company's stock are sold short.
View Haemonetics' Short Interest
.

When is Haemonetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our HAE earnings forecast
.

How were Haemonetics' earnings last quarter?

Haemonetics Co. (NYSE:HAE) released its quarterly earnings results on Tuesday, February, 7th. The medical instruments supplier reported $0.85 earnings per share for the quarter, beating analysts' consensus estimates of $0.79 by $0.06. The medical instruments supplier had revenue of $305.30 million for the quarter, compared to the consensus estimate of $300.47 million. Haemonetics had a net margin of 9.87% and a trailing twelve-month return on equity of 20.13%. Haemonetics's revenue for the quarter was up 17.5% on a year-over-year basis. During the same quarter last year, the firm earned $0.84 EPS.

What guidance has Haemonetics issued on next quarter's earnings?

Haemonetics updated its FY 2024 earnings guidance on Friday, May, 12th. The company provided earnings per share (EPS) guidance of $3.45-$3.75 for the period, compared to the consensus EPS estimate of $3.40. The company issued revenue guidance of $1.22 billion-$1.25 billion, compared to the consensus revenue estimate of $1.22 billion.

What is Christopher Simon's approval rating as Haemonetics' CEO?

48 employees have rated Haemonetics Chief Executive Officer Christopher Simon on Glassdoor.com. Christopher Simon has an approval rating of 63% among the company's employees. This puts Christopher Simon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Haemonetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Haemonetics investors own include NVIDIA (NVDA), Micron Technology (MU), Johnson & Johnson (JNJ), AbbVie (ABBV), Citigroup (C), Align Technology (ALGN), Chipotle Mexican Grill (CMG), Netflix (NFLX) and Pfizer (PFE).

What is Haemonetics' stock symbol?

Haemonetics trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."

Who are Haemonetics' major shareholders?

Haemonetics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Wellington Management Group LLP (7.09%), Fisher Asset Management LLC (2.07%), Geode Capital Management LLC (1.87%), Royce & Associates LP (1.67%), Dimensional Fund Advisors LP (1.39%) and Boston Partners (1.32%). Insiders that own company stock include Anila Lingamneni, Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Laurie A Miller, Mark W Kroll, Mark W Kroll, Michelle L Basil, Michelle L Basil, Richard J Meelia, Stewart W Strong and William P Mr Burke.
View institutional ownership trends
.

How do I buy shares of Haemonetics?

Shares of HAE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Haemonetics' stock price today?

One share of HAE stock can currently be purchased for approximately $88.14.

How much money does Haemonetics make?

Haemonetics (NYSE:HAE) has a market capitalization of $4.45 billion and generates $1.17 billion in revenue each year. The medical instruments supplier earns $115.40 million in net income (profit) each year or $2.23 on an earnings per share basis.

How many employees does Haemonetics have?

The company employs 3,034 workers across the globe.

How can I contact Haemonetics?

Haemonetics' mailing address is 125 Summer Street, Boston MA, 02110. The official website for the company is www.haemonetics.com. The medical instruments supplier can be reached via phone at (781) 848-7100, via email at gerry.gould@haemonetics.com, or via fax at 781-848-5106.

This page (NYSE:HAE) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -